Budget Impact of Tyrosine Kinase Inhibitor Discontinuation in Chronic Myeloid Leukemia With Sustained Deep Molecular Response

Published:March 07, 2021DOI:


      • Systematically offering tyrosine kinase inhibitors (TKI) discontinuation to patients with chronic myeloid leukemia (CML) in sustained deep molecular remission (DMR) would save up to €25.5 million over 5 years.
      • It has already been shown that TKI discontinuation in patients with CML in sustained DMR is safe and generalizable. The savings we report here is another argument for generalizing TKI discontinuation for patients with CML in sustained DMR.



      Tyrosine kinase inhibitors (TKIs) account for the vast majority of healthcare expenditure on patients with chronic myeloid leukemia (CML), and it has been demonstrated that TKI discontinuation in patients in long-term deep molecular remission (DMR) is safe and improves quality of life. Our objective was to estimate the budget impact of TKI discontinuation in CML patients in long-term DMR from the perspective of the French healthcare system.


      This analysis was conducted over a 5-year time horizon using a Markov model with cycles of 6 months. Transition probabilities were estimated through systematic reviews and meta-analyses. Costs were estimated from the French National Claims Database. Monte Carlo simulations were performed to take into account the uncertainty surrounding model parameters. Sensitivity analyses were carried out by varying the size of the target population and the cost of TKIs.


      Over a 5-year period and for a target population of 100 patients each year eligible and agreeing to stop TKI, the TKI discontinuation strategy would save €25.5 million (95% confidence interval –39.3 to 70.0). In this model, the probability that TKI discontinuation would be more expensive than TKI continuation was 12.0%. In sensitivity analyses, mean savings ranged from €14.9 million to €62.9 million.


      This study provides transparent, reproducible, and interpretable results for healthcare professionals and policy makers. Our results clearly show that innovative healthcare strategies can benefit both the healthcare system and patients. Savings from generalizing TKI discontinuation in CML patients in sustained DMR should yield health gains for other patients.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic and Personal


      Subscribe to Value in Health
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Le Guyader-Peyrou S.
        • Belot A.
        • Maynadié M.
        • et al.
        Cancer incidence in France over the 1980-2012 period: hematological malignancies.
        Rev Epidemiol Sante Publique. 2016; 64: 103-112
        • Delord M.
        • Foulon S.
        • Cayuela J.M.
        • Rousselot P.
        • Bonastre J.
        The rising prevalence of chronic myeloid leukemia in France.
        Leuk Res. 2018; 69: 94-99
        • Huang X.
        • Cortes J.
        • Kantarjian H.
        Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy.
        Cancer. 2012; 118: 3123-3127
        • Bower H.
        • Björkholm M.
        • Dickman P.W.
        • Höglund M.
        • Lambert P.C.
        • Andersson T.M.-L.
        Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population.
        J Clin Oncol. 2016; 34: 2851-2857
        • Baccarani M.
        • Deininger M.W.
        • Rosti G.
        • et al.
        European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.
        Blood. 2013; 122: 872-884
        • Le Guyader-Peyrou S.
        • Defossez G.
        • Dantony E.
        • et al.
        Estimations nationales de l’incidence et de la mortalité par cancer en France métropolitaine entre 1990 et 2018 - Volume 2: Hémopathies malignes: Étude à partir des registres des cancers du réseau Francim.
        • Mounié M.
        • Costa N.
        • Gauthier M.
        • et al.
        Evaluation of the cost of chronic myeloid leukaemia management in the Midi-Pyrénées.
        Rev Epidemiol Sante Publique. 2016; 64: S155
        • Saußele S.
        • Richter J.
        • Hochhaus A.
        • Mahon F.-X.
        The concept of treatment-free remission in chronic myeloid leukemia.
        Leukemia. 2016; 30: 1638-1647
        • Mahon F.-X.
        • Réa D.
        • Guilhot J.
        • et al.
        Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.
        Lancet Oncol. 2010; 11: 1029-1035
        • Ross D.M.
        • Branford S.
        • Seymour J.F.
        • et al.
        Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study.
        Blood. 2013; 122: 515-522
        • Lee S.-E.
        • Choi S.Y.
        • Song H.-Y.
        • et al.
        Imatinib withdrawal syndrome and longer duration of imatinib have a close association with a lower molecular relapse after treatment discontinuation: the KID study.
        Haematologica. 2016; 101: 717-723
        • Imagawa J.
        • Tanaka H.
        • Okada M.
        • et al.
        Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial.
        Lancet Haematol. 2015; 2: e528-e535
        • Dulucq S.
        • Cyril Astrugue C.
        • Etienne G.
        • Mahon F.X.
        • Benard A.
        Risk of molecular recurrence after tyrosine kinase inhibitors discontinuation in chronic myeloid leukemia patients: a systematic review of literature with a meta-analysis of studies over the last 10 years.
        Br J Haematol. 2020; 189: 452-468
        • Park J.S.
        • Lee S.E.
        • Jeong S.H.
        • et al.
        Change of health-related profiles after Imatinib cessation in chronic phase chronic myeloid leukemia patients.
        Leuk Lymphoma. 2016; 57: 341-347
        • Mahon F.X.
        • Boquimpani C.M.
        • Takahashi N.
        • et al.
        Patient-reported quality of life before and after stopping treatment in the ENESTop trial of treatment-free remission for patients with chronic myeloid leukemia in chronic phase.
        Blood. 2016; 128: 1891
        • Petrova A.
        • Chelysheva E.
        • Shukhov O.
        • et al.
        Quality of life in chronic myeloid leukemia patients with deep molecular response who stopped therapy by tyrosine kinase inhibitors: interim results of russian prospective multicenter trial RU-SKI.
        Blood. 2018; 132: 3023
        • Hochhaus A.
        • Baccarani M.
        • Silver R.T.
        • et al.
        European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.
        Leukemia. 2020; 34: 966-984
        • Rea D.
        • Ame S.
        • Berger M.
        • et al.
        Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group.
        Cancer. 2018; 124: 2956-2963
        • 19Ferrero D.
        • Cerrano M.
        • Crisà E.
        • Aguzzi C.
        • Giai V.
        • Boccadoro M.
        How many patients can proceed from chronic myeloid leukaemia diagnosis to deep molecular response and long-lasting imatinib discontinuation? A real life experience.
        Br J Haematol. 2017; 176: 669-671
        • Marin D.
        • Bazeos A.
        • Mahon F.X.
        • et al.
        Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib.
        J Clin Oncol. 2010; 28: 2381-2388
        • Briggs A.
        • Sculpher M.
        • Claxton K.
        Decision Modelling for Health Economic Evaluation.
        OUP, Oxford2006
        • Sullivan S.D.
        • Mauskopf J.A.
        • Augustovski F.
        • et al.
        Budget impact analysis-principles of good practice: report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force.
        Value Health. 2014; 17: 5-14
        • Husereau D.
        • Drummond M.
        • Petrou S.
        • et al.
        Consolidated Health Economic Evaluation Reporting Standards (CHEERS)—explanation and elaboration: a report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force.
        Value Health. 2013; 16: 231-250
        • Caro J.J.
        • Briggs A.H.
        • Siebert U.
        • Kuntz K.M.
        ISPOR-SMDM Modeling Good Research Practices Task Force. Modeling good research practices—overview: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--1.
        Value Health. 2012; 15: 796-803
        • Bezin J.
        • Duong M.
        • Lassalle R.
        • et al.
        The national healthcare system claims databases in France, SNIIRAM and EGB: powerful tools for pharmacoepidemiology.
        Pharmacoepidemiol Drug Saf. 2017; 26: 954-962
        • Haute Autorité de Santé
        Choix méthodologiques pour l’évaluation économique à la HAS.
        • Institut National de la Statistique et des études économiques
        Prix à la consommation.
        • Gunnarsson N.
        • Sandin F.
        • Höglund M.
        • et al.
        Population-based assessment of chronic myeloid leukemia in Sweden: striking increase in survival and prevalence.
        Eur J Haematol. 2016; 97: 387-392
        • Institut National d’Etudes démographiques
        Taux de mortalité par sexe et âge en 2014.
        • Barendregt J.J.
        The life table method of half cycle correction: getting it right.
        Med Decis Making. 2014; 34: 283-285
        • Newman E.
        • Kingsley K.
        An introduction to the method of moments.
        Computer Physics Comm. 1991; 68: 1-18
        • Ministère des solidarités et de la santé
        Base de données publique des médicaments.
        • Matsuki E.
        • Sakurai M.
        • Karigane D.
        • Kikuchi T.
        • Shimizu T.
        Second attempt to discontinue TKI in CML patients who have sustained CMR for over 2 years is rarely successful even with the use of second generation TKIs.
        Blood. 2016; 128: 1887
        • Etienne G.
        • Guilhot J.
        • Rea D.
        • et al.
        Long-term follow-up of the French Stop Imatinib (STIM1) Study in patients with chronic myeloid leukemia.
        J Clin Oncol. 2017; 35: 298-305
        • Rea D.
        • Nicolini F.E.
        • Tulliez M.
        • et al.
        Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study.
        Blood. 2017; 129: 846-854
        • Mahon F.X.
        • Rea D.
        • Guilhot J.
        • et al.
        Long-term follow-up after imatinib cessation for patients in deep molecular response: the update results of the STIM1 study.
        Blood. 2013; 122 (Abstract 255)
        • Saussele S.
        • Richter J.
        • Guilhot J.
        • et al.
        Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial.
        Lancet Oncol. 2018; 19: 747-757
        • Elias F.
        • Gebran A.
        • Said C.
        • Beker R.V.
        • Ammar W.
        Budget impact of treatment-free remission in treating chronic-phase Philadelphia-positive chronic myeloid leukemia in Lebanon.
        J Glob Oncol. 2019; 5: 1-7
        • Etienne G.
        • Dulucq S.
        • Faberes C.
        • et al.
        A single center evaluation of cost savings related to treatment-free remission in chronic myeloid leukemia patients: the prerequisites of a pharmaco-economy larger study.
        Br J Haematol. 2020; 189: e97-e100
        • Yamazaki K.
        • Inagaki N.
        • Moldaver D.
        • Viana R.
        • Kimura S.
        Budget impact analysis of treatment-free remission in nilotinib-treated Japanese chronic myeloid leukemia patients.
        Cancer Sci. 2020; 111: 2526-2535
        • Hughes T.P.
        • Ross D.M.
        Moving treatment-free remission into mainstream clinical practice in CML.
        Blood. 2016; 128: 17-23